Study #2024-0436
A phase 1b/2 open-label study of APVO436 in combination with Venetoclax and Azacitidine in patients with newly diagnosed acute myeloid leukemia (AML).
MD Anderson Study Status
Enrolling
Treatment Agent
APVO436, Venetoclax, Azacitidine
Description
A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia (AML)
Study phase:
Phase I
Physician name:
Gautam Borthakur
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.